Abstract
More than 110 million individuals will suffer from cognitive loss worldwide by the year 2050 with a majority of individuals presenting with Alzheimer’s disease (AD). Yet, successful treatments for etiologies that involve β-amyloid (Aβ) toxicity in AD remain elusive and await novel avenues for drug development. Here we show that Wnt1 inducible signaling pathway protein 1 (WISP1/CCN4) controls the post-translational phosphorylation of Akt1, p70S6K, and AMP activated protein kinase (AMPK) to the extent that tuberous sclerosis complex 2 (TSC2) (Ser1387) phosphorylation, a target of AMPK, is decreased and TSC2 (Thr1462) phosphorylation, a target of Akt1, is increased. The ability of WISP1 to limit TSC2 activity allows WISP1 to increase the activity of p70S6K, since gene silencing of TSC2 further enhances WISP1 phosphorylation of p70S6K. However, a minimal level of TSC2 activity is necessary to modulate WISP1 cytoprotection that may require modulation of mTOR activity, since gene knockdown of TSC2 impairs the ability of WISP1 to protect microglia against apoptotic membrane phosphatidylserine (PS) exposure, nuclear DNA degradation, mitochondrial membrane depolarization, and cytochrome c release during Aβ exposure.
Keywords: Alzheimer’s disease, Amyloid, Akt, CCN4, Microglia, mTOR, PI 3-K, p70S6K, TSC2, Tuberin, WISP1
Current Neurovascular Research
Title:Tuberous Sclerosis Protein 2 (TSC2) Modulates CCN4 Cytoprotection During Apoptotic Amyloid Toxicity in Microglia
Volume: 10 Issue: 1
Author(s): Yan Chen Shang, Zhao Zhong Chong, Shaohui Wang and Kenneth Maiese
Affiliation:
Keywords: Alzheimer’s disease, Amyloid, Akt, CCN4, Microglia, mTOR, PI 3-K, p70S6K, TSC2, Tuberin, WISP1
Abstract: More than 110 million individuals will suffer from cognitive loss worldwide by the year 2050 with a majority of individuals presenting with Alzheimer’s disease (AD). Yet, successful treatments for etiologies that involve β-amyloid (Aβ) toxicity in AD remain elusive and await novel avenues for drug development. Here we show that Wnt1 inducible signaling pathway protein 1 (WISP1/CCN4) controls the post-translational phosphorylation of Akt1, p70S6K, and AMP activated protein kinase (AMPK) to the extent that tuberous sclerosis complex 2 (TSC2) (Ser1387) phosphorylation, a target of AMPK, is decreased and TSC2 (Thr1462) phosphorylation, a target of Akt1, is increased. The ability of WISP1 to limit TSC2 activity allows WISP1 to increase the activity of p70S6K, since gene silencing of TSC2 further enhances WISP1 phosphorylation of p70S6K. However, a minimal level of TSC2 activity is necessary to modulate WISP1 cytoprotection that may require modulation of mTOR activity, since gene knockdown of TSC2 impairs the ability of WISP1 to protect microglia against apoptotic membrane phosphatidylserine (PS) exposure, nuclear DNA degradation, mitochondrial membrane depolarization, and cytochrome c release during Aβ exposure.
Export Options
About this article
Cite this article as:
Chen Shang Yan, Zhong Chong Zhao, Wang Shaohui and Maiese Kenneth, Tuberous Sclerosis Protein 2 (TSC2) Modulates CCN4 Cytoprotection During Apoptotic Amyloid Toxicity in Microglia, Current Neurovascular Research 2013; 10 (1) . https://dx.doi.org/10.2174/1567202611310010005
DOI https://dx.doi.org/10.2174/1567202611310010005 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Headspace Gas Chromatography Methods and their Potential Industrial Applications
Current Chromatography Editorial:Cannabis: Neurological Correlates in Abuse and Medical Use
CNS & Neurological Disorders - Drug Targets Editorial: Second International Conference on Novel Psychoactive Substances (NPSs): Keynote Addresses and Conference Abstracts
Current Drug Abuse Reviews Construction of a Neuro-Immune-Cognitive Pathway-Phenotype Underpinning the Phenome of Deficit Schizophrenia
Current Topics in Medicinal Chemistry BDNF Serum Concentrations Show No Relationship with Diagnostic Group or Medication Status in Neurodegenerative Disease
Current Alzheimer Research Masked Hypertension and Diabetes
Current Hypertension Reviews Mycotoxins Levels in Human Milk: A Menace to Infants and Children Health
Current Nutrition & Food Science Bacteria From Marine Sponges: A Source of New Drugs
Current Drug Metabolism Development and Characterization of Biodegradable Polymeric Microspheres of Metformin Hydrochloride
Nanoscience & Nanotechnology-Asia Cytogenomic Bioinformatics: Practical Issues
Current Bioinformatics Reviewing the Cardiovascular Complications of HIV Infection After the Introduction of Highly Active Antiretroviral Therapy
Current Drug Targets - Cardiovascular & Hematological Disorders Modulators of Voltage-Dependent Calcium Channels for the Treatment of Nervous System Diseases
Recent Patents on CNS Drug Discovery (Discontinued) Evaluation of the Effects of a New Drug on Brain Leukocyte Infiltration in an Experimental Model of Autoimmune Encephalomyelitis
Letters in Drug Design & Discovery Chemotherapeutic Effects of Acridine Derivatives
Medicinal Chemistry Reviews - Online (Discontinued) Multi-Target Drugs for Neglected Diseases
Current Pharmaceutical Design CADD Modeling of Multi-Target Drugs Against Alzheimer's Disease
Current Drug Targets Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Treating Sarcopenia in Older and Oldest Old
Current Pharmaceutical Design Current Status of Newer Carbapenems
Current Medicinal Chemistry Serum Interleukin-33 is a Predictor of Depression in Patients with Acute Ischemic Stroke
Current Neurovascular Research